导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.38% | 1657/4773 |
| 近一周 | -2.52% | 2450/5462 |
| 近一月 | -4.52% | 2535/5421 |
| 近一季 | -6.45% | 2096/5209 |
| 近半年 | 1.51% | 1041/4920 |
| 近一年 | 5.47% | 1595/4366 |
| 近两年 | 61.57% | 1167/2954 |
| 近三年 | 18.05% | 1545/2253 |
| 成立以来 | 109.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.43% 2787/4961 |
11.26% 2353/5312 |
- - |
- - |
| 2025 | 26.50% 1626/4813 |
-2.25% 2864/3635 |
-1.86% 3281/4076 |
30.74% 1159/4524 |
0.86% 1712/4813 |
| 2024 | -3.68% 2219/3463 |
-3.41% 1499/2808 |
-11.14% 2508/3014 |
19.05% 895/3129 |
-5.74% 2585/3463 |
| 2023 | -17.68% 1753/2656 |
2.64% 1324/2280 |
-12.30% 2180/2385 |
-4.05% 1050/2515 |
-4.68% 1142/2655 |
| 2022 | -20.49% 974/2207 |
-21.34% 1616/1919 |
14.16% 208/2016 |
-13.61% 931/2113 |
2.49% 917/2208 |
| 2021 | -4.27% 946/1822 |
-6.83% 1042/1255 |
12.72% 316/1330 |
-14.34% 1366/1466 |
6.41% 218/1822 |
| 2020 | 73.58% 61/1250 |
-2.29% 257/1028 |
28.20% 113/1067 |
15.77% 195/1164 |
19.69% 71/1184 |
| 2019 | 60.02% 54/1092 |
33.95% 125/754 |
5.22% 16/804 |
5.15% 163/850 |
7.98% 371/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 中金MSCI质量C VS. 长安沪深300非周期A(740101) |